Revenue generation has stalled completely, with the company reporting zero revenue in 2024Q4 while still incurring $559.5K in SG&A expenses.
| Sales/Revenue | 0 | 79.84K | 147.54K | 0 | 0 |
| Revenue Growth % | -100% | -45.88% | - | - | - |
| Cost of Goods Sold | 0 | 48.92K | 94.87K | 0 | 0 |
| COGS % of Revenue | - | 61.28% | 64.31% | - | - |
| Gross Profit | 0 | 30.92K | 52.66K | 0 | 0 |
| Gross Margin % | - | 38.72% | 35.69% | - | - |
| Gross Profit Growth % | -100% | -41.29% | - | - | - |
| Operating Expenses | 2.95M | 3.13M | 3.25M | 647.62K | 529.62K |
| OpEx % of Revenue | - | 3924.04% | 2200.09% | - | - |
| Selling, General & Admin | 1.27M | 1.7M | 1.55M | 463.73K | 230.52K |
| SG&A % of Revenue | - | 2126.49% | 1048.19% | - | - |
| Research & Development | 276.06K | 665.03K | 529.02K | 277.06K | 342.36K |
| R&D % of Revenue | - | 832.93% | 358.57% | - | - |
| Other Operating Expenses | 1.4M | 770.18K | 1.17M | -93.16K | -43.26K |
| Operating Income | -2.95M | -3.1M | -3.19M | -647.62K | 0 |
| Operating Margin % | - | -3885.31% | -2164.39% | - | - |
| Operating Income Growth % | 5.03% | 2.85% | -393.07% | - | - |
| EBITDA | -1.73M | -1.88M | -1.98M | -589.68K | -527.23K |
| EBITDA Margin % | - | -2349.19% | -1340.69% | - | - |
| EBITDA Growth % | 7.55% | 5.17% | -235.44% | -11.84% | - |
| D&A (Non-Cash Add-back) | 1.21M | 1.23M | 1.22M | 57.95K | 2.39K |
| EBIT | -2.96M | -3.1M | -3.19M | -647.62K | -529.62K |
| Net Interest Income | -600.22K | -404.07K | -175.63K | -1.3K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 585.12K | 403.52K | 174.5K | 1.3K | 0 |
| Other Income/Expense | -600.22K | -404.07K | -175.63K | -1.3K | -529.62K |
| Pretax Income | -3.55M | -3.51M | -3.37M | -648.92K | -529.62K |
| Pretax Margin % | - | -4391.39% | -2283.44% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | -154.03K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 29.08% |
| Net Income | -3.55M | -3.51M | -3.37M | -648.92K | -375.59K |
| Net Margin % | - | -4391.39% | -2283.44% | - | - |
| Net Income Growth % | -1.14% | -4.08% | -419.15% | -72.78% | - |
| Net Income (Continuing) | -3.55M | -3.51M | -3.37M | -648.92K | -375.59K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | -0.37 | -0.36 | -0.07 | -0.16 |
| EPS Growth % | 100% | -2.78% | -423.26% | 57% | - |
| EPS (Basic) | 0.00 | -0.37 | -0.36 | -0.07 | -0.16 |
| Diluted Shares Outstanding | 0 | 9.44M | 9.44M | 9.44M | 2.35M |
| Basic Shares Outstanding | 0 | 9.44M | 9.44M | 9.44M | 2.35M |
| Dividend Payout Ratio | - | - | - | - | - |
Imminent liquidity and insolvency
As indicated by the most recent financial disclosures, Gelteq's revenue growth has stalled at -100% year-over-year, reflecting a complete absence of commercial activity and the apparent termination of previous pilot programs that were intended to validate the company's proprietary gel-based delivery technology in the marketplace.
The transition from nominal revenue in 2022 to zero reported revenue in recent quarters suggests a fundamental failure to convert R&D milestones into sustainable commercial contracts. Investors should monitor whether this reflects a strategic pivot or an inability to secure market adoption for the company's specialty delivery platform.
Based on reported figures, the company continues to incur significant operating expenses, including $559.5K in SG&A during 2024Q4, despite generating no revenue, which highlights a cost structure that appears disconnected from the current lack of commercial scale or active product manufacturing operations.
The persistence of high administrative and laboratory expenses in the absence of top-line growth indicates a high fixed-cost burden that is likely unsustainable. This cost structure suggests that the company is currently consuming its remaining capital reserves primarily to maintain its public listing and basic R&D infrastructure.
According to the latest income statement data, the company's operating income remains deeply negative at -$966.6K for 2024Q4, demonstrating that the business lacks the necessary scale to achieve operating leverage or cover its fixed R&D and administrative expenses through its current business model.
Without a revenue base to absorb fixed costs, the company's operating margins remain non-existent, rendering traditional leverage analysis moot. The current financial trajectory implies that any future path to profitability would require a massive, non-linear increase in commercial volume that has yet to materialize.
With cash and equivalents reported at a precarious $24,522, the company faces an acute liquidity crisis that, as noted in recent filings, suggests an inability to sustain operations without immediate, likely highly dilutive, external financing to bridge the gap between current R&D efforts and commercialization.
The extreme scarcity of cash relative to quarterly burn rates warrants significant caution, as it limits management's ability to execute on its strategic roadmap. This financial position may force the company into unfavorable financing terms, which could further erode shareholder value and complicate future capital allocation.
Quick answers to the most common questions about buying GELS stock.
For fiscal year 2024, Gelteq Limited Ordinary Shares (GELS) reported total revenue of $0.0M.
Gelteq Limited Ordinary Shares (GELS) reported a net loss of $3.5M for the fiscal year ending 2024.